The final results of the unique Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) are updated: ASCOT is the largest study of hypertension ever undertaken in Europe involving >19,000 patients and also includes the study of lipid management in >10,000 patients. The results of ASCOT have had a significant impact on the prevention of coronary heart disease (CHD) and other vascular events by lowering blood pressure and reducing cholesterol. It provides the healthcare professional with critically important new insights into: - The comparative efficacy of specific combinations of antihypertensive drugs. - The value of reducing CHD risk by achieving control of blood pressure and effective lowering of cholesterol. This updated book provides clinicians with a revised comprehensive and detailed review of the final results of ASCOT and some further analyses of the trial data. Additionally, the authors discuss implications of ASCOT for daily practice.
Preface 1: The history of a trial 2: Hypertension trial review - ASCOT in context 3: ASCOT blood pressure-lowering arm (ASCOT-BPLA): methods, results and impact 4: ASCOT - cardiovascular benefits in subjects with diabetes 5: New-onset diabetes and impact of glycaemia on cardiovascular events 6: Multiple risk factor intervention: evidence of benefits from ASCOT 7: Combination therapy 8: Health economic review 9: Guidelines practice and future projects